Skip to main navigation Skip to search Skip to main content

A 24 Week Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years

Project: Research

Project Details

StatusFinished
Effective start/end date10/3/16 → 10/2/21

Funding

  • Pharmaceutical Research Associates Incorporated: $94,825.00